lifestyle.digitaladblog.com

Author: OKYO Pharma LTD

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

April 29, 2026
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

April 7, 2026
OKYO Pharma Announces Chairman and Founder Acquires Shares

March 19, 2026
OKYO Pharma Announces Director Acquires Shares

March 19, 2026
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

March 19, 2026
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

March 18, 2026
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

February 23, 2026
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

February 14, 2026
OKYO Pharma Announces Public Offering of Ordinary Shares

February 14, 2026
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

February 13, 2026